As medical technology continuously evolves, Ancerix proudly unveils its plan to develop a new orthopedic toolkit. Having licensed patents from The University of Arizona, Ancerix aims to provide new options to the orthopedic surgical domain.
Dr. Daniel Latt (center), Chief Medical Officer, earned his medical degree and doctorate in bioengineering from the University of Pittsburgh in 2002. He then completed residency training in orthopaedic surgery at McGill University in Montreal, a sports fellowship at Kaiser in San Diego, and a foot and ankle fellowship at Duke. Dr. Latt is an Associate Professor of Orthopaedic Surgery and Biomedical Engineering at the University of Arizona. LinkedIn Profile.
Dr. Ramsés Galaz (left), Chief Technology Officer, has over 18 years of experience in mechanical design, biomedical engineering, and manufacturing engineering. Ramses has guided 44 international projects developing medical devices. He is CEO of GSE Biomedical and a professor at Tecnológico de Monterrey. LinkedIn Profile.
John Buttery (right), President and CEO, is an experienced professional focused on technology. His expertise in sales management, strategic alliances, and bilingual skills position him uniquely for global business engagements. LinkedIn Profile.
In patients, excessive bone growth often blocks easy access to screws, making their removal cumbersome.
Bone integrity, often weakened due to infections, becomes a challenge. This can result in screw rotation, making the removal process even more complex.
One of the monumental challenges orthopedic surgeons face is the removal of broken intramedullary nails. If not addressed efficiently, these broken pieces can lead to further complications.
The primary focus lies in refining the Ancerix Toolkit. This means leveraging standard materials and simplifying manufacturing processes to create a comprehensive set of instruments housed in a sterilization box.
Upon commencing manufacturing, the strategy expands to include active participation in trade shows to showcase the product's utility. Additionally, efforts will be directed toward recruiting distributors, informing buying services, and disseminating information to orthopedic surgeons.
The emphasis will be on the sales of this innovative add-on product. Given the established market, its competitive pricing, and the clear articulation of its value, it targets a user group that is likely to be receptive.
Join 4,000+ surgeons in the Ancerix community for exclusive company insights, industry news, and expert articles delivered to your inbox. Stay ahead of the curve – subscribe now!